Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Olink Bioscience's Proseek Multiplex CVD I 96x96

Premium

Olink Bioscience this week launched Proseek Multiplex CVD I 96x96, a new protein biomarker panel for cardiovascular disease.

According to Olink, its new multiplex immunoassay allows the analysis of 92 cardiovascular-related protein biomarkers across 96 samples simultaneously. The assay requires one microliter of sample is required. The panel contains known cardiovascular and inflammatory markers as well as a few exploratory proteins that serve as new cardiovascular markers.

Olink said that the new panel can be run on Fluidigm's BioMark HD System. Using the BioMark HD System with the Proseek Multiplex CVD I 96x96, a researcher can now obtain results for up to 9,216 reactions in just a few hours, the firm said.

BioArray News discussed the new panel and other company developments with its CEO Simon Fredriksson during a recent visit to the firm's base in Uppsala, Sweden (BAN 10/15/2013).

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.